Mesoblast awaits urgent FDA meeting as cash burn continues - Stockhead
Mesoblast says it burned through $US28.2 million in the third quarter, leaving it with $US108.1 million cash on hand as it awaits some key catalysts.
Mesoblast awaits urgent FDA meeting as cash burn continues - Stockhead
Mesoblast says it burned through $US28.2 million in the third quarter, leaving it with $US108.1 million cash on hand as it awaits some key catalysts.